CoChat
Sign Up
Cited by 1,320Sirtuins and Resveratrol in MedicineAdipose Tissue and MetabolismMetabolism, Diabetes, and Cancer

Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans

Open access
Timmers, Silvie, Konings, Ellen, Bilet, Lena, Houtkooper, Riekelt H., van de Weijer, Tineke, Goossens, Gijs H., Hoeks, Joris, van der Krieken, Sophie +9 more·2011·Cell Metabolism
DOI 10.1016/j.cmet.2011.10.002PMC PMC3880862
Open this paper in CoChat — free accountOpen PDF

Abstract

Summary Resveratrol is a natural compound that affects energy metabolism and mitochondrial function and serves as a calorie restriction mimetic, at least in animal models of obesity. Here we treated 11 healthy, obese men with placebo and 150 mg/day resveratrol in a randomized double-blind cross-over study for 30 days. Resveratrol significantly reduced sleeping- and resting metabolic rate. In muscle, resveratrol activated AMPK, increased SIRT1 and PGC-1α protein levels, increased citrate synthase activity without change in mitochondrial content, and improved muscle mitochondrial respiration on a fatty acid-derived substrate. Furthermore, resveratrol elevated intramyocellular lipid levels, and decreased intrahepatic lipid content, circulating glucose, triglycerides, alanine-aminotransferase, and inflammation markers. Systolic blood pressure dropped and HOMA index improved after resveratrol. In the postprandial state, adipose tissue lipolysis and plasma fatty acid and glycerol decreased. In conclusion, we demonstrate that 30 days of resveratrol supplementation induces metabolic changes in obese humans, mimicking the effects of calorie restriction.

Integrity signals

Registry

Crossref · 10.1016/j.cmet.2011.10.002

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

0 of 48 cited sources checked · 0 supported · 0 flagged

  • Findingown data

    Resveratrol activated AMPK in skeletal muscle.

    “In muscle, resveratrol activated AMPK, increased SIRT1 and PGC-1α protein levels, increased citrate synthase activity without change in mitochondrial content, and improved muscle mitochondrial respiration on a fatty acid-derived substrate.”
    • Also stated in: § Molecular mechanism of resveratrol treatment · plain
      “increased AMPK phosphorylation was observed in muscle biopsies of the resveratrol-treated subjects (figure 3A, S1A).”
    Quote in the paperSubstantial claim
  • Findingown data

    Resveratrol increased SIRT1 protein levels in muscle.

    “increased SIRT1 and PGC-1α protein levels”
    • Also stated in: § Mitochondrial metabolism · plain
      “protein content of the AMPK downstream effector SIRT1 (Canto et al., 2009), as well as the mitochondrial master regulator PGC-1α were significantly increased after 30 days of resveratrol (figure 3C, S1C)”
    Quote in the paperSubstantial claim
  • Findingown data

    Resveratrol improved the HOMA index.

    “HOMA index improved after resveratrol.”
    • Also stated in: § Study design and plasma biochemistry · hedged
      “resulting in a lower HOMA-index, indicative of improved insulin sensitivity (table 2).”
    Quote in the paperSubstantial claim
  • Findingown data

    Resveratrol improved muscle mitochondrial respiration on a fatty acid-derived substrate.

    “improved muscle mitochondrial respiration on a fatty acid-derived substrate.”
    • Also stated in: § Mitochondrial metabolism · plain
      “state 3 respiration upon malate + octanoyl-carnitine + glutamate (MOG) was significantly higher in subjects receiving resveratrol (figure 3H).”
    Quote in the paperSubstantial claim
  • Findingown data

    Resveratrol decreased systemic inflammation markers.

    “and inflammation markers.”
    • Also stated in: § Study design and plasma biochemistry · plain
      “resveratrol also lowered some markers of systemic inflammation, for including IL-6 and TNF-α (table 2).”
    Quote in the paperNot a substantial claim
  • Classified as probably not a substantial claim. 16
  • May combine two claims. 24
  • The quote only partly states this claim. 2

  • Probably not a substantial claim: may not pass S1 (asserted), S3 (load-bearing), S4 (based). May combine two claims. The quote only partly states this claim.

    Findingnone given

    In the postprandial state, resveratrol tended to lower adipose tissue lipolysis, but the reduction was not statistically significant.

    “In the postprandial state, adipose tissue lipolysis and plasma fatty acid and glycerol decreased.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Resveratrol did not change diet-induced thermogenesis or physical activity index.

    “No differences were observed in diet-induced thermogenesis or physical activity index (table 3).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Peak glucose and insulin responses after a mixed meal occurred at 30 min for placebo and 60 min for resveratrol.

    “The peak glucose and insulin responses after consuming a liquid test meal were reached after 30 min for placebo and after 60 min for resveratrol (figure 1A,B).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    After resveratrol treatment, expression levels of inflammatory pathway genes, plasma levels of several inflammatory markers, and leukocyte numbers decreased.

    “Another indication that global health was improved upon resveratrol treatment was the decreased expression levels of genes of inflammatory pathways, as were plasma levels of several inflammatory markers, and leukocyte numbers.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingcitation

    The human dose of 150 mg/day resveratrol is 133-266 fold lower than mouse doses of 200-400 mg/kg/day, but human plasma resveratrol levels averaged 231 ng/ml, higher than mouse levels of 10-120 ng/ml.

    “although the dosage of 150 mg of resveratrol per day is around 133-266 fold lower compared to the high doses of 200 to 400 mg/kg/day used to supplement mice (Baur et al., 2006; Lagouge et al., 2006), plasma resveratrol levels in our human intervention (231 ng/ml on average during the 30 days) were even higher than those obtained in mice (10-120 ng/ml) (Lagouge et al., 2006).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Lagouge et al., 2006 source

      Not checked in the free run.

  • May combine two claims.

    Findingown data

    Microarray analysis found 469 genes differentially expressed between placebo and resveratrol, with 219 increased and 250 decreased.

    “We found 469 genes to be differentially expressed between placebo and resveratrol supplementation, 219 of which were increased and 250 decreased (figure 2A).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    No resveratrol or dihydroresveratrol was detected in placebo plasma, while both were present in resveratrol-supplemented subjects.

    “Whereas no resveratrol or DHR could be detected in the placebo group, both compounds were present in plasma of resveratrol-supplemented subjects (table 2, levels at day 30 are shown and representative for the whole intervention period).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    Resveratrol did not alter postprandial triglyceride or lactate responses.

    “Resveratrol did not alter postprandial triglyceride and lactate responses (data not shown).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Gene set enrichment analysis showed upregulation of mitochondrial oxidative phosphorylation gene sets and downregulation of inflammation pathways after resveratrol.

    “Several gene sets related to mitochondrial oxidative phosphorylation were upregulated, whereas pathways linked to inflammation were downregulated upon resveratrol supplementation (table S3).”
    Quote in the paperSubstantial claim

  • The quote only partly states this claim.

    Findingown data

    Resveratrol supplementation for 30 days reduced systolic blood pressure by 5 mmHg in healthy obese men.

    “A striking finding in our study was the resveratrol-induced reduction of systolic blood pressure by 5 mmHg.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Twenty-four-hour respiratory quotient tended to be higher after resveratrol, largely due to higher daytime RQ.

    “Respiratory quotient (RQ) values over 24 hours tended to be higher after resveratrol supplementation, which was largely accounted for by higher RQ values during the daytime (table 3, the complete time-course for the RQ and the energy expenditure over 24 hours is shown in table S2).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Resveratrol was efficiently metabolized, with plasma DHR exceeding resveratrol after an overnight fast.

    “measurement of DHR confirmed that resveratrol was efficiently metabolized, especially as the plasma levels of DHR exceeded those of resveratrol after an overnight fast.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Safety parameters showed no changes, and no adverse events were reported.

    “Furthermore, there were no effects on safety parameters and no adverse events were reported.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    Most observed effects were modest but consistently pointed toward beneficial metabolic adaptations.

    “Although most of the effects that we observed were modest, they were very consistently pointing towards beneficial metabolic adaptations.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    Short-term dietary restriction in humans lowers metabolic rate, improves insulin sensitivity, and reduces cardiovascular risk factors.

    “Although short-term dietary restriction has metabolic effects in humans such as lowering metabolic rate (Heilbronn et al., 2006), improving insulin sensitivity (Larson-Meyer et al., 2006; Lim et al., 2011) and reducing cardiovascular risk factors (Lefevre et al., 2009)”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites Heilbronn et al., 2006 source

      Not checked in the free run.

    • cites Larson-Meyer et al., 2006 source

      Not checked in the free run.

    • cites Lim et al., 2011 source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Reducing calorie intake by 30-50% below ad libitum or every-other-day feeding delays age-related disease onset, improves stress resistance, and slows functional decline.

    “Reduction of calorie intake to 30-50% below ad libitum levels, or every-other-day feeding, can delay the onset of age-related diseases, improve stress resistance, and decelerate functional decline (Barger et al., 2003; Goodrick et al., 1990; McCay et al., 1935).”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites Barger et al., 2003 source

      Not checked in the free run.

    • cites Goodrick et al., 1990 source

      Not checked in the free run.

    • cites McCay et al., 1935

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Resveratrol was identified as the most potent SIRT1 activator in an in vitro screen.

    “Resveratrol, a natural polyphenolic compound present in various dietary components such as mulberries, peanuts, grapes and red wine, was identified as the most potent activator of SIRT1 (Howitz et al., 2003).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Howitz et al., 2003 source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Resveratrol may not directly activate SIRT1 but acts through AMPK, though direct SIRT1 activation is not fully excluded.

    “Recently, it was shown, however, that resveratrol may not activate SIRT1 directly (Beher et al., 2009; Pacholec et al., 2010), but rather exerts its effects on SIRT1 through activation of AMPK (Baur et al., 2006; Canto et al., 2009; Canto et al., 2010; Feige et al., 2008; Hawley et al., 2010; Um et al., 2010), although additional direct SIRT1 activation is not completely excluded (Dai et al., 2010”
    Quote in the paperNot a substantial claim0 of 3 sources checked
    • cites Beher et al., 2009 source

      Not checked in the free run.

    • cites Pacholec et al., 2010 source

      Not checked in the free run.

    • cites Baur et al., 2006 source

      Not checked in the free run.

  • Classified as probably not a substantial claim.

    Premisecitation

    Sirtuins are considered an important molecular target for calorie restriction mimetics.

    “In that respect, sirtuins are considered an important molecular target (Canto and Auwerx, 2009).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Canto and Auwerx, 2009

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Resveratrol is a natural compound that influences energy metabolism and mitochondrial function and acts as a calorie restriction mimetic in animal obesity models.

    “resveratrol treatment in mice fed a high calorie diet consistently improved various health parameters including glucose homeostasis, endurance and survival (Baur et al., 2006; Lagouge et al., 2006; Pearson et al., 2008; Sun et al., 2007), and has therefore been suggested to act as a calorie restriction mimetic.”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites Baur et al., 2006 source

      Not checked in the free run.

    • cites Lagouge et al., 2006 source

      Not checked in the free run.

    • cites Pearson et al., 2008 source

      Not checked in the free run.

  • May combine two claims.

    Study design and conductown data

    The trial was randomized, double-blind, crossover, with 11 healthy obese men receiving placebo and 150 mg/day resveratrol for 30 days separated by a four-week washout.

    “Here we treated 11 healthy, obese men with placebo and 150 mg/day resveratrol in a randomized double-blind cross-over study for 30 days.”
    • Also stated in: § Study design and plasma biochemistry · plain
      “Subjects participated in two experimental trials: (1) a placebo and (2) a resveratrol (150 mg/day (99%); resVida™) (provided by DSM Nutritional Products, Ltd) condition, in a randomized double-blind crossover design with a four-week wash-out period.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: The four-week washout period was sufficient to eliminate carryover effects between the placebo and resveratrol conditions.

  • May combine two claims.

    Interpretationown data

    The gene expression effects of resveratrol in humans are highly similar to those in mice treated with resveratrol, though more pronounced in mice.

    “Importantly, these effects are highly similar to the effects observed in mice treated with resveratrol (figure 2C), even though the effects in the latter are more pronounced, probably due to longer treatment time and their identical genetic and environmental background.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Lagouge et al., 2006 source

      Not checked in the free run.

  • May combine two claims.

    Interpretationown data

    Resveratrol mimics the effect of calorie restriction and endurance training.

    “Again, here our data suggest that resveratrol mimics the effect of calorie restriction and endurance training.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    In rodents, resveratrol lowers blood pressure.

    “and even to lower blood pressure (Rivera et al., 2009).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Rivera et al., 2009 source

      Not checked in the free run.

  • May combine two claims.

    Study design and conductown data

    Plasma resveratrol measurement demonstrated compliance and indicated good absorption.

    “Whereas measurement of plasma resveratrol demonstrated compliance to the study protocol and indicated that the compound was well absorbed”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    In rodents, resveratrol reduces heart rate.

    “to reduce heart rate (Lagouge et al., 2006)”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Lagouge et al., 2006 source

      Not checked in the free run.

  • Classified as probably not a substantial claim.

    Premisecitation

    Resveratrol reduces hepatic lipid synthesis in rats.

    “Consistent with data in rats, where resveratrol has been shown to reduce hepatic lipid synthesis (Ahn et al., 2008; Arichi et al., 1982), we observed reduced IHL content.”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites Ahn et al., 2008 source

      Not checked in the free run.

    • cites Arichi et al., 1982 source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    In healthy non-obese individuals, six months of calorie restriction improved cardiovascular risk, as shown by reduced blood pressure.

    “Similarly, healthy non-obese individuals also improved their cardiovascular risk after six months of calorie restriction as evidenced by a reduction in blood pressure (Lefevre et al., 2009).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Lefevre et al., 2009 source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Endurance training can lower intrahepatic lipid content.

    “Recent data suggest that endurance training is also able to lower IHL content (Kantartzis et al., 2009)”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Kantartzis et al., 2009 source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    In rodents, resveratrol causes vasodilatation and improves aortic endothelial function in diabetic mice.

    “In rodents, resveratrol is also vasoactive and has been shown to cause vasodilatation and to improve aortic endothelial function in diabetic mice (Wang et al., 2011)”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Wang et al., 2011 source

      Not checked in the free run.

  • Classified as probably not a substantial claim. May combine two claims.

    Study design and conductown data

    The trial was a crossover, double-blind, randomized comparison of placebo and resVida, with four weeks between conditions.

    “Subjects participated in two experimental trials: a placebo and a resVida™ (150mg/day trans-resveratrol (99.9%) (provided by DSM Nutritional Products, Ltd) condition, in a randomized double-blind crossover design with a four-week wash-out period.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data

    Ethical approval for the protocol was granted by the medical ethics committee at Maastricht University Medical Centre.

    “The study protocol was reviewed and approved by the Medical Ethical Committee of Maastricht University Medical Centre (MUMC+).”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim.

    Study design and conductown data

    Subjects' adherence to the dietary and supplement restrictions was verified through their verbal report.

    “Compliance with these instructions was confirmed by verbal declaration of the subjects.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: Verbal reports from subjects accurately reflect their adherence to dietary and supplement restrictions.

  • Classified as probably not a substantial claim.

    Study design and conductcitation

    Microdialysis successfully assessed resveratrol's lipolytic effects in adipose tissue and skeletal muscle in 10 subjects.

    “In 10 subjects, the lipolytic effects of resveratrol in adipose tissue and skeletal muscle were successfully determined by microdialysis, essentially according to (Goossens et al., 2004).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Goossens et al., 2004 source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data

    Plasma resveratrol metabolites were quantified by mass spectrometry on days 0, 7, 14, 21, 29, and 30 as a compliance check.

    “To check compliance, resveratrol metabolites were measured by mass spectrometry in plasma on day 0, 7, 14, 21, 29 and 30 as described in the supplemental methods.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationown data

    At the concentration tested, resVida was safe and well tolerated.

    “Therefore, resVida was safe and well tolerated at the tested concentration.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data

    All participants gave written informed consent before the study began.

    “All study participants gave written informed consent before initiation of the study.”
    Quote in the paperNot a substantial claim
37 of 37

  • The paper relies on this without support.

    Calorie restriction is unlikely to gain widespread compliance for creating a desirable metabolic profile.

    “eating less for the sake of creating a desirable metabolic profile is unlikely to gain widespread compliance.”

  • The paper relies on this without support.

    No human studies have systematically examined the in vivo metabolic effects of resveratrol.

    “However, so far no human studies have been reported that have systematically examined the metabolic effects of resveratrol in vivo.”

  • The paper relies on this without support.

    Sleeping metabolic rate is the component of human energy metabolism most sensitive to metabolic changes and is not affected by physical activity.

    “It should be noted that SMR is the component of human energy metabolism that is most sensitive to metabolic changes—as it is not affected by physical activity—and small differences in sleeping energy expenditure can be detected with high accuracy.”

  • The paper relies on this without support.

    The four-week washout period was sufficient to eliminate carryover effects between the placebo and resveratrol conditions.

    “in a randomized double-blind crossover design with a four-week wash-out period.”

  • The paper relies on this without support.

    Verbal reports from subjects accurately reflect their adherence to dietary and supplement restrictions.

    “Compliance with these instructions was confirmed by verbal declaration of the subjects.”

  • The paper relies on this without support.

    HOMA-index is a valid marker of insulin sensitivity.

    “Indeed, HOMA-index was improved after resveratrol, suggesting favorable effects on insulin sensitivity.”
6 of 6

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a placebo-controlled, double-blind cross-over study, 150 mg/day of resveratrol treatment for 30 days significantly reduced blood glucose and insulin concentrations in otherwise healthy obese men.

    “In a placebo-controlled, double-blind cross-over study, 150 mg/day of resveratrol treatment for 30 days significantly reduced blood glucose and insulin concentrations in otherwise healthy obese men [84].”

    From Mitochondrial Adaptation in Skeletal Muscle: Impact of Obesity, Caloric Restriction, and Dietary Compounds (2024) · cites this paper as [84]

  • Dietary resveratrol supplementation has anti-obesity effects, potentially by mimicking metabolic effects of long-term caloric restriction and improving adipose tissue function and insulin sensitivity in obese models.

    “Recent studies have also revealed anti-obesity effects of dietary resveratrol supplementation [82, 83], potentially by mimicking the metabolic effects of long-term caloric restriction [84] and improving adipose tissue function and insulin sensitivity in obese model [85].”

    From Mitochondrial Adaptation in Skeletal Muscle: Impact of Obesity, Caloric Restriction, and Dietary Compounds (2024) · cites this paper as [84]

  • In muscle biopsy of healthy obese males supplemented with resveratrol, increased AMPK phosphorylation, SIRT1 and PGC1α expression, and citrate synthase activity were reported.

    “In the muscle biopsy of healthy obese males supplemented with resveratrol, increased AMPK phosphorylation, SIRT1 and PGC1α expression, and citrate synthase activity were reported [84].”

    From Mitochondrial Adaptation in Skeletal Muscle: Impact of Obesity, Caloric Restriction, and Dietary Compounds (2024) · cites this paper as [84]

  • Resveratrol up-regulates expression of genes associated with mitochondrial oxidative phosphorylation while down-regulating those involved in inflammation.

    “Additionally, resveratrol up-regulates the expression of genes associated with mitochondrial oxidative phosphorylation, while down-regulating those involved in inflammation [84].”

    From Mitochondrial Adaptation in Skeletal Muscle: Impact of Obesity, Caloric Restriction, and Dietary Compounds (2024) · cites this paper as [84]

  • Resveratrol may affect the activity of AMPK, SIRT-1, and PGC-1α, all altered in the metabolic abnormalities present in patients with obesity.

    “Resveratrol may affect the activity of various intracellular targets such as adenosine monophosphate-activated protein kinase (AMPK), the deacetylating enzyme sirtuin-1 (SIRT-1), and the peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), all altered in the metabolic abnormalities present in patients with obesity [12,13].”

    From The Role of Resveratrol Administration in Human Obesity (2021) · cites this paper as [13]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Resveratrol purity is reported differently

    Minor

    The same 150 mg/day supplement is described as 99% trans-resveratrol in the Results and 99.9% in the study-design methods.

1 of 1

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H., van de Weijer, T., Goossens, G. H., Hoeks, J., van der Krieken, S., Ryu, D., Kersten, S., Moonen-Kornips, E., Hesselink, M. K. C., Kunz, I., Schrauwen-Hinderling, V. B., Blaak, E. E., Auwerx, J., & Schrauwen, P.
Affiliations
  • Maastricht University Medical Centre (NL)
  • École Polytechnique Fédérale de Lausanne (CH)
  • Wageningen University & Research (NL)
  • DSM (Switzerland) (CH)
Corresponding author
Schrauwen, Patrick
ORCID
Venue
Cell Metabolism
Publisher
Elsevier BV
Published
2011-11
Volume
14
Issue
5
Pages
612-622
ISSN
1550-4131 (ISSN-L)
DOI
10.1016/j.cmet.2011.10.002
PMC
PMC3880862
OpenAlex
W2165722123
Semantic Scholar
87ec47fbe7791b76e5ed69fbac343fb2d8a31311
Cited by
1,320
References
55
Citations by year
2026: 60 · 2025: 63 · 2024: 57 · 2023: 70 · 2022: 62 · 2021: 95 · 2020: 98 · 2019: 75 · 2018: 96 · 2017: 98 · 2016: 94 · 2015: 105 · 2014: 119 · 2013: 131 · 2012: 85
FWCI
52.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Socio-Environmental Systems Modeling (acceptedVersion)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (918.96.618)
  • DSM Nutritional Products
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
  • Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
resveratrol, caloric restriction mimetics, obesity, energy metabolism, AMPK, SIRT1, PGC-1α, mitochondrial function, intramyocellular lipid, liver lipids, insulin resistance, adipose tissue lipolysis, postprandial lipemia, blood pressure, inflammation
MeSH terms
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Resveratrol, AMP-Activated Protein Kinase Kinases, Adipose Tissue, Alanine Transaminase, Blood Glucose, Blood Pressure, Citrate (si)-Synthase, Double-Blind Method, Energy Metabolism, Fatty Acids, Glycerol, Heat-Shock Proteins, Humans, Liver, Male, Middle Aged, Mitochondria, Muscle, Netherlands, Obesity, Protein Kinases, Stilbenes, Switzerland, Transcription Factors, Triglycerides, Muscle, Skeletal, Cross-Over Studies, Caloric Restriction, Sirtuin 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-06.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-06.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review